Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) said its precision immunotherapy will be used in women suffering ovarian cancer.
In what’s called a second expansion cohort of the company’s phase I/II MATINS clinical trial, Faron drug Clevegen will continue to be assessed for safety and efficacy.
The treatment has been designed to target a range of solid tumours and people with colorectal cancer have previously received it.
Faron chief executive, Dr Markku Jalkanen, said data collected so far in the MATINS trial are “highly encouraging”.
He added that Clevegen establishing itself as a potential immunotherapy capable of reducing or supressing (downregulating) a range of major immune checkpoints that may inhibit the body’s own response to the disease.
“Initiation of this additional expansion cohort signals our commitment to rapidly progress the development of Clevegen in patients with limited effective treatment options," he added.